Literature DB >> 2568929

Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers.

N Inotsume1, M Nishimura, S Fujiyama, K Sagara, T Sato, Y Imai, H Matsui, M Nakano.   

Abstract

The pharmacokinetics of the H2-receptor antagonist famotidine, after oral administration of a 20 mg tablet, has been studied in 10 elderly patients with normal renal function (CLCR greater than or equal to 59 ml.min-1, Mean = 80 ml.min-1), 5 elderly patients with renal insufficiency (CLCR less than or equal to 38 ml.min-1, Mean = 15 ml.min-1), and 6 healthy young volunteers. Elimination half-life in the elderly patients with renal insufficiency was significantly prolonged compared to the elderly patients with normal renal function and the young volunteers. The correlation coefficient between creatinine clearance and the elimination rate constant of famotidine was 0.672. Mean urinary recovery of unchanged drug up to 24 h in the young volunteers was 44%. The mean renal clearance of famotidine in the young volunteers (270 ml.min-1) was substantially greater than the creatinine clearance, 128 ml.min-1, which suggests the possibility of tubular secretion of famotidine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568929     DOI: 10.1007/BF00558079

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Clinical pharmacology of famotidine.

Authors:  J L Smith
Journal:  Digestion       Date:  1985       Impact factor: 3.216

3.  Inhibition of gastric secretion by a new H2-antagonist, YM-11170 in healthy subjects.

Authors:  M Miwa; N Tani; T Miwa
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1984-04

4.  Blood level of cimetidine in relation to age.

Authors:  A Redolfi; E Borgogelli; E Lodola
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

5.  Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.

Authors:  T Takabatake; H Ohta; M Maekawa; Y Yamamoto; Y Ishida; H Hara; S Nakamura; Y Ushiogi; M Kawabata; N Hashimoto
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Ranitidine bioavailability and kinetics in normal male subjects.

Authors:  D C Garg; D J Weidler; F N Eshelman
Journal:  Clin Pharmacol Ther       Date:  1983-04       Impact factor: 6.875

7.  Ranitidine kinetics in normal subjects.

Authors:  N P Chau; P Y Zech; N Pozet; A Hadj-Aissa
Journal:  Clin Pharmacol Ther       Date:  1982-06       Impact factor: 6.875

Review 8.  Famotidine: a notable lack of drug interactions.

Authors:  T J Humphries
Journal:  Scand J Gastroenterol Suppl       Date:  1987

9.  The effect of famotidine on renal function in patients with renal insufficiency.

Authors:  P A Abraham; J A Opsahl; C E Halstenson; A N Chremos; G R Matzke; W F Keane
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

10.  Famotidine, a new H2-receptor antagonist. Effect on parietal, nonparietal, and pepsin secretion in man.

Authors:  J L Smith; M A Gamal; A N Chremos; D Y Graham
Journal:  Dig Dis Sci       Date:  1985-04       Impact factor: 3.199

View more
  11 in total

Review 1.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

Review 2.  Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists.

Authors:  M Lazzaroni; G Bianchi Porro
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

Review 3.  Switching drug availability from prescription only to over-the-counter status. Are elderly patients at increased risk?

Authors:  S I Benrimoj; J H Langford; M G Bowden; E J Triggs
Journal:  Drugs Aging       Date:  1995-10       Impact factor: 3.923

4.  Removal of famotidine by haemodialysis in elderly anuric patients.

Authors:  N Inotsume; M Nishimura; M Nakano; S Fujiyama; K Sagara; T Sato; K Matsushita; Y Imai; H Matsui
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.

Authors:  U Gladziwa; U Klotz
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 6.  Prescribing policy for antiulcer treatment in the elderly.

Authors:  G Bianchi Porro; M Lazzaroni
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

Review 7.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

Review 8.  Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure.

Authors:  U Gladziwa; U Koltz
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

9.  Pharmacokinetics of famotidine in patients with cirrhosis and ascites.

Authors:  G Vinçon; C Baldit; P Couzigou; F Demotes-Mainard; L Elouaer-Blanc; B Bannwarth; B Begaud
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Comparison and analysis of delirium induced by histamine h(2) receptor antagonists and proton pump inhibitors in cancer patients.

Authors:  Shiro Fujii; Hitoshi Tanimukai; Yujiro Kashiwagi
Journal:  Case Rep Oncol       Date:  2012-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.